Major Drugs to Hit Global Transthyretin Amyloidosis Market in 2018, Predicts Koncept Analytics in Its New Report Published at MarketPublishers.com
16 Aug 2017 • by Natalie Aster
LONDON – ATTR amyloidosis is a rare disorder, triggered by the accumulation of abnormal protein (amyloid) deposits in different tissues of the body. Amyloid deposits damage the function and structure of the organs where they are retained, and they can affect practically any part of the body.
The market lacks higher efficacy ATTR drugs to date, however, they are anticipated to go on sale by end-2018. Patisiran and IONIS-TTRrx are amid the most prospective ATTR drug candidates. Currently, the usage of off-label medications and therapies is popular in countering the progression of the disease.
The world ATTR market is poised to witness rapid growth following the launch of ATTR therapeutic drugs, mainly owing to expanding African-American population, rising spending on healthcare, and robust economic advance. Meantime, growth of the emerging market is restrained by the stiff regulations, expensiveness of ATTR drugs, erroneous diagnosis of ATTR disease, and downsides of clinical trials.
New research report “Global Transthyretin Amyloidosis (ATTR) Market: Industry Analysis & Outlook (2018-2025)” drawn up by Koncept Analytics is devoted to an in-depth, unbiased analysis of the development of the market worldwide, focusing on the regional markets of the USA and Europe. The research publication sheds light on the key trends, growth drivers and burning issues pertaining to the market. It offers detailed profiles of the key players covering their key financials and growth strategies. The overall competitive scenario is also presented in the study.
Companies discussed include: Ionis Pharmaceuticals, Pfizer, Prothena Corporation and Alnylam Pharmaceuticals.
Follow to the Koncept Analytics page to find a complete collection of the publisher’s new insightful research reports.
The Market Publishers, Ltd.